Company: WHWK
Filing Date: 2025-03-31
Form Type: 8-K/A
Source: 0001193125-25-068845
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: 8-K/A
Chunk 1
---
� If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note On March 26, 2025, Whitehawk Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report the consummation of the sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (the “Divestiture”) pursuant to the Stock Purchase Agreement entered into with KAKEN INVESTMENTS INC., a Delaware corporation, KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc. on December 19, 2024. As disclosed in the Initial Report, this Current Report on Form 8-K/A is beingfiled to amend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. Noother changes are being made to the Initial Report. The pro forma financial information included in this Current Report on Form 8-K/A has beenpresented for informational purposes only and is not necessarily indicative of the pro forma financial position or results of operations that would have been realized had the Divestiture occurred as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that the Company will experience after the Divestiture. This Current Report on Form 8-K/A should beread in conjunction with the Initial Report, which provides a more complete description of the Divestiture. Item 9.01. Financial Statements and Exhibits. (b) The unaudited pro forma condensed consolidated financial information of the Company as of and for the fiscal year ended December 31, 2024 as required by Item 9.01(b) is attached as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporatedherein by reference. (d) Exhibits

| Exhibit Number |     | Description                                                                  |
| 99.1           |     | Unaudited Pro Forma Condensed Consolidated Financial Information.            |
| 104            |     | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of